Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06911112
PHASE3

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Sponsor: Neurocrine Biosciences

View on ClinicalTrials.gov

Summary

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-03-31

Completion Date

2027-07

Last Updated

2025-12-01

Healthy Volunteers

No

Interventions

DRUG

NBI-1065845

NBI-1065845 tablets

DRUG

Placebo

Matching placebo tablets

Locations (10)

Neurocrine Clinical Site

Huntsville, Alabama, United States

Neurocrine Clinical Site

Glendale, California, United States

Neurocrine Clinical Site

Irvine, California, United States

Neurocrine Clinical Site

Miami, Florida, United States

Neurocrine Clinical Site

Tampa, Florida, United States

Neurocrine Clinical Site

Atlanta, Georgia, United States

Neurocrine Clinical Site

Boston, Massachusetts, United States

Neurocrine Clinical Site

Saint Charles, Missouri, United States

Neurocrine Clinical Site

The Bronx, New York, United States

Neurocrine Clinical Site

Mason, Ohio, United States